Regeneron Pharmaceuticals Inc on Tuesday said its experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients, enhancing its chances of becoming a treatment for the disease that has killed over a million people worldwide."We hope these data will support an EUA" (emergency use authorization) from the U.S.
Food and Drug Administration, Regeneron Chief Scientific Officer George Yancopoulos said on a conference call.The FDA can authorize emergency use of a drug before completing its review for a formal approval.The treatment, REGN-COV2, is also being studied for use in hospitalized patients, and for prevention of infection in people who have been exposed to COVID-19.